Cytox

Cytox Develops a Simple Genetic-Based Blood Test for Assessing and Diagnosing Alzheimer’s Risk at an Early StageAlzheimer’s disease affects more than 26 million people worldwide and is growing as life expectancy increases. There is currently no cure for Alzheimer’s, but large-scale international initiatives are underway to find treatments for multiple drugs in clinical development. Cytox, together with Affymetrix (part of Thermo Fisher Scientific), has commercially launched their test to support pharmaceutical and biotechnology companies in developing novel therapies.